DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (CIK 1009258) reported 24 SEC Form 4 insider transactions across 5 companies over the past 18 months (most recent 2026-06-18). Recent activity: Buy NUVL (3,444 shares), Buy PBLS (122,990 shares), Buy PBLS (122,990 shares), Buy PBLS (149,238 shares), Buy PBLS (149,238 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-18 | Nuvalent, Inc. (NUVL) | Director | Buy | 3,444 | $0 |
| 2026-06-11 | Parabilis Medicines, Inc. (PBLS) | Insider | Buy | 122,990 | $0 |
| 2026-06-11 | Parabilis Medicines, Inc. (PBLS) | Insider | Buy | 122,990 | $0 |
| 2026-06-11 | Parabilis Medicines, Inc. (PBLS) | Insider | Buy | 149,238 | $0 |
| 2026-06-11 | Parabilis Medicines, Inc. (PBLS) | Insider | Buy | 149,238 | $0 |
| 2026-06-11 | Parabilis Medicines, Inc. (PBLS) | Insider | Buy | 260,992 | $0 |
| 2026-06-11 | Parabilis Medicines, Inc. (PBLS) | Insider | Buy | 260,992 | $0 |
| 2026-06-11 | Parabilis Medicines, Inc. (PBLS) | Insider | Buy | 407,132 | $0 |
| 2026-06-11 | Parabilis Medicines, Inc. (PBLS) | Insider | Buy | 407,132 | $0 |
| 2026-03-02 | Larimar Therapeutics, Inc. (LRMR) | Director | Buy | 2.0M | $10.0M |
| 2026-03-02 | Larimar Therapeutics, Inc. (LRMR) | Director | Buy | 1.1M | $5.4M |
| 2026-03-02 | Larimar Therapeutics, Inc. (LRMR) | Director | Buy | 831,978 | $4.2M |
| 2026-03-02 | Larimar Therapeutics, Inc. (LRMR) | Director | Buy | 1.1M | $5.4M |
| 2025-11-24 | Nuvalent, Inc. (NUVL) | Director | Sell | 371,287 | $35.4M |
| 2025-11-24 | Nuvalent, Inc. (NUVL) | Director | Sell | 371,287 | $35.4M |
| 2025-08-04 | Larimar Therapeutics, Inc. (LRMR) | Director | Buy | 3.4M | $10.8M |
| 2025-08-04 | Larimar Therapeutics, Inc. (LRMR) | Director | Buy | 3.4M | $10.8M |
| 2025-08-04 | Larimar Therapeutics, Inc. (LRMR) | Director | Buy | 2.6M | $8.3M |
| 2025-07-01 | ARS Pharmaceuticals, Inc. (SPRY) | Insider | Sell | 370,075 | $6.8M |
| 2025-07-01 | ARS Pharmaceuticals, Inc. (SPRY) | Insider | Sell | 370,074 | $6.8M |
| 2025-06-20 | Nuvalent, Inc. (NUVL) | Director | Buy | 2,647 | $0 |
| 2025-06-20 | Nuvalent, Inc. (NUVL) | Director | Buy | 2,647 | $0 |
| 2025-03-03 | BiomX Inc. (PHGE) | Director | Buy | 353,249 | $328,522 |
| 2025-03-03 | BiomX Inc. (PHGE) | Director | Buy | 353,249 | $328,522 |
Source: SEC Form 4 filings · as of 2026-06-18